BetterLife Pharma closes US$100 million common share, pre-funded warrant offering

• BetterLife Pharma closed a public offering raising about USD 100 million, issuing 447,041,840 common shares at CAD 0.25.
• Also issued 107,958,160 pre-funded warrants at CAD 0.25, exercisable for one common share at CAD 0.00001.
• Agents hold a 15% over-allotment option through Oct. 17, 2026, lifting potential gross proceeds to about USD 115 million.
• Net proceeds earmarked for BETR-001 Phase 1A, parallel Phase 1B in cluster headache and migraine, then Phase 2 trials.
• Post-closing capital structure: 618,007,179 common shares outstanding, 107,958,160 pre-funded warrants outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609171041NEWSFILECNPR____20260917_314747_1) on September 17, 2026, and is solely responsible for the information contained therein.